Chronic nicotine treatment up-regulates α3 and α7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y

Molecular Pharmacology

Volumn 51, Issue 5, 1997, Pages 776-784

  Peng, Xiao ^a   Gerzanich, Volodymyr ^a   Anand, René ^a   Wang, Fan ^a   Lindstrom, Jon ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBACHOL; CHOLINERGIC RECEPTOR; CURARE; DIHYDRO BETA ERYTHROIDINE; MECAMYLAMINE; MESSENGER RNA; MONOCLONAL ANTIBODY; NICOTINE; RECEPTOR SUBTYPE; TRITIUM; TUBOCURARINE CHLORIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MEMBRANE BINDING; NEUROBLASTOMA CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR UPREGULATION; XENOPUS LAEVIS;

EID: 0030972169     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.5.776     Document Type: Article

References (41)

1. Wonnacott, S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. 11:216-219 (1990).
2. Schwartz, R. D., and K. J. Kellar. In vivo regulation of acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J. Neurochem. 45:427-433 (1985).
3. 3H]nicotine binding sites in human brain. J. Neurochem. 50:1243-1247 (1988).
4. Flores, C. M., S. W. Rogers, L. A. Pabreza, B. B. Wolfe, and K. J. Kellar. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:31-37 (1992).
5. Marks, M. J., J. R. Pauly, S. D. Gross, E. S. Deneris, B. I. Hermans, S. F. Heinemann, and A. C. Collins. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12:2765-2784 (1992).
6. Pauly, J., M. Marks, S. Robinson, J. van de Kamp, and A. Collins. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing α4 or β2 mRNA levels. J. Pharmacol. Exp. Ther. 278:361-369 (1996).
7. Marks, M. J., J. A. Stitzel, and A. C. Collins. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J. Pharmacol. Exp. Ther. 235:619-628 (1985).
8. Bhat, R. V., S. Turner, S. Selvagg, M. Marks, and A. Collins. Regulation of the brain nicotine receptors by chronic agonist infusion. J. Neurochem. 4:345-350 (1991).
9. Whiting, P., R. Schoepfer, J. Lindstrom, and T. Priestley. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol. Pharmacol. 40:463-472 (1991).
10. Whiting, P., and J. Lindstrom. Pharmacological properties of immunoisolated neuronal nicotinic receptors. J. Neurosci. 6:3061-3069 (1986).
11. Lindstrom, J., R. Schoepfer, W. Conroy, and P. Whiting. Structural and functional heterogeneity of nicotinic receptors. Ciba Found. Symp. 152: 23-42 (1990).
12. Gerzanich, V., X. Peng, F. Wang, G. Wells, R. Anand, S. Fletcher, and J. Lindstrom. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 48:774-782 (1995).
13. Peng, X., V. Gerzanich, R. Anand, P. J. Whiting, and J. Lindstrom. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol. Pharmacol. 46:523-530 (1994).
14. Schoepfer, R., W. G. Conroy, P. Whiting, M. Gore, and J. Lindstrom. Brain α-bungarotoxin binding protein cDNAs and mAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron 5:35-48 (1990).
15. Couturier, S., D. Bertrand, J. M. Matter, M. C. Hernandez, S. Bertrand, N. Millar, S. Valera, T. Barkas, and M. Ballivet. A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron 5:847-856 (1990).
16. Elgoyhen, A. B., D. S. Johnson, J. Boulter, D. E. Vetter, and S. Heinemann. α9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79:705-715 (1994).
17. Anand, R., X. Peng, J. J. Ballesta, and J. Lindstrom. Pharmacological characterization of α-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: contrasting properties of α7 and α8 subunit-containing subtypes. Mol. Pharmacol. 44:1046-1050 (1993).
18. Barrantes, G. E., A. Rogers, J. Lindstrom, and S. Wonnacott. α-Bungaro-toxin binding sites in rat hippocampal and cortical cultures: initial characterization, colocalization with α7 subunits and upregulation by chronic nicotine treatment. Brain Res. 20:228-236 (1995).
19. Zhang, X., Z. H. Gong, E. Hellstrom-Lindahl, and A. Nordberg. Regulation of α4β2 nicotinic acetylcholine receptors in M10 cells following treatment with nicotinic agents. Neuroreport 6:313-317 (1994).
20. Gopalakrishnan, M., L. M. Monteggia, D. J. Anderson, E. J. Molinari, M. Piattoni-Kaplan, D. Donnelly-Roberts, S. P. Arneric, and J. P. Sullivan. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine α4β2 receptor. J. Pharmacol. Exp. Ther. 276:289-297 (1996).
21. Smith, M. A., J. F. Margiotta, A. J. Franco, J. M. Lindstrom, and D. K. Berg. Cholinergic modulation of an acetylcholine receptor-like antigen on the surface of chick ciliary ganglion neurons in cell culture. J. Neurosci. 6:946-953 (1986).
22. Peng, X., M. Katz, V. Gerzanich, R. Anand, and J. Lindstrom. Human α7 acetylcholine receptor: cloning of the α7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional α7 homomers expressed in Xenopus oocytes. Mol. Pharmacol. 45:546-554 (1994).
23. Wang, F., V. Gerzanich, G. Wells, R. Anand, X. Peng, K. Keyser, and J. Lindstrom. Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2, and β4 subunits. J. Biol. Chem. 271:17656-17665 (1996).
24. Lukas, R., S. Norman, and L. Lucero. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol. Cell. Neurosci. 4:1-12 (1993).
25. Quick, M., J. Choremis, J. Komourian, R. Lukas, and E. Puchacz. Similarity between rat brain nicotinic α bungarotoxin in receptors and stably expressed α bungarotoxin binding sites. J. Neurochem. 67:145-154 (1996).
26. Ross, R. A., B. A. Spengler, and J. L. Biedler. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. 71:741-749 (1983).
27. Tzartos, S., S. Hochschwender, P. Vasquez, and J. Lindstrom. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 15:185-194 (1987).
28. Chomczynski, P., and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159 (1987).
29. Benowitz, N., H. Porchet, and P. Jacob. Pharmacokinetics, metabolism, and pharmacodynamics of nicotine, in Nicotine Psychopharmacology (S. Wonnacott, M. Russell, I. Stolerman, eds.). Oxford Science Publications, Oxford, England, 112-157 (1990).
30. Conroy, W., and Berg, D. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J. Biol. Chem. 270:4424-4431 (1995).
31. Collins, A. C., E. Romm, and J. M. Wehner. Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors. Brain Res. Bull. 25:373-379 (1990).
32. Pauly, J. R., M. J. Marks, S. D. Gross, and A. C. Collins. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J. Pharmacol. Exp. Ther. 258:1127-1136 (1991).
33. Sanderson, E. M., A. L. Drasdo, K. McCrea, and S. Wonnacott. Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region specific. Brain Res. 617:349-352 (1993).
34. Siegel, H. N., and R. J. Lukas. Nicotinic agonists regulate α-bungarotoxin binding sites of TE671 human medulloblastoma cells. J. Neurochem. 50: 1272-1278 (1988).
35. Lindstrom, J., D. Shelton, and Y. Fujii. Myasthenia gravis. Adv. Immunol. 42:233-284 (1988)
36. Luther, M., R. Schoepfer, P. Whiting, B. Casey, Y. Blatt, M. S. Montal, M. Montal, and J. Lindstrom. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. 9:1082 (1989).
37. Bencherif, M. Fowler, K., Lukas, R., and Lippiello, P. Mechanisms of upregulation of neuronal nicotinic acetylcholine receptors in clonal cell lines and primary cultures of fetal rat brain. J. Pharmacol. Exp. Ther. 275:987-994 (1995).
38. Stadel, J., B. Strulovivi, P. Nambi, T. Lavin, M. Briggs, M. Caron, and R. Lefkowitz. Desensitization of the β-adrenergic receptor of frog erythrocytes: recovery and characterization of the down-regulated receptors in sequestered vesicles. J. Biol. Chem. 258:3032-3038 (1986).
39. Hsu, Y. N., J. Amin, D. S. Weiss, and L. Wecker. Sustained nicotine exposure differentially affects α3β2 and α4β2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66:667-675 (1996).
40. Lindstrom, J., R. Anand, X. Peng, V. Gerzanich, F. Wang, and Y. Li. Neuronal nicotinic receptor subtypes. Ann. N. Y. Acad. Sci. 757:100-116 (1995).
41. Benowitz, N. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36:597-613 (1996).